...
首页> 外文期刊>Iranian Journal of Microbiology >Clinical response and outcome of pneumonia due to multi-drug resistant Acinetobacter baumannii in critically ill patients
【24h】

Clinical response and outcome of pneumonia due to multi-drug resistant Acinetobacter baumannii in critically ill patients

机译:重症患者多重耐药鲍曼不动杆菌引起的肺炎的临床反应和结局

获取原文

摘要

Background and Objectives: The frequency of multi-drug resistant Acinetobacter spp. infections is increasing in Iran. Considering availability of limited therapeutic options, clinical response and outcome of ventilator-associated pneumonia due to multi-drug resistant A.baumannii were evaluated in critically ill patients.Materials and Methods: In this prospective study, 29 patients with carbapenem resistance A. baumannii ventilator-associated pneumonia were enrolled. Endotracheal aspirate specimens were analyzed according to the clinical and laboratory standard institute instructions in the hospital’s microbiology laboratory. Demographics, clinical, microbiological and laboratory findings were collected for each patient during the treatment course. Therapeutic empirical regimen, change in antibiotic regimen following receiving antibiogram results, clinical and microbiological responses, duration of ICU stay and outcome were collected for each recruited individual.Results: All of A. baumanii isolates were resistant to pipracillin-tazobactam, ceftriaxon, amikacin and ciprofloxacin. The resistance rate of A. baumanii species was 41.4% for ampicillin/sulbactabm and 93.1% for meropenem. Patients received either meropenem/colistin (51.7%) or meropenem/ampicillin-sulbactam (48.3%) as the treatment regimens based on the antimicrobial susceptibility patterns of isolates. Ventilator-associated pneumonia clinical response, improvement and failure achieved in 15 (51.7%), 8 (27.6%) and 6 (20.7%) of the patients respectively. Microbiological eradication and intermediate status were observed in 9/29 (31%) and 11/29 (37.9%) of patients, respectivelyConclusion: The antibiotic regimens showed comparable efficacy in treatment of VAP due to MDR A. baumannii but mortality rate was high. Considering widespread and high mortality rates associated with MDR infections, applying infection control and antibiotic stewardship programs in hospitals are essential.
机译:背景与目的:多重耐药性不动杆菌属的频率。伊朗的感染正在增加。考虑到有限的治疗选择的可用性,对重症患者进行了多重耐药性鲍曼不动杆菌引起的呼吸机相关性肺炎的临床反应和结局评估。材料与方法:在这项前瞻性研究中,有29例对碳青霉烯耐药的鲍曼不动杆菌呼吸机招募了相关性肺炎。根据医院微生物实验室的临床和实验室标准研究所的指示对气管内抽吸物进行了分析。在治疗过程中收集了每个患者的人口统计学,临床,微生物学和实验室检查结果。收集每个患者的治疗经验方案,抗生素方案改变后的抗生素方案,临床和微生物学应答,ICU停留时间和结局。结果:鲍曼不动杆菌的所有分离株均对哌普西林-他唑巴坦,头孢曲松,丁胺卡那霉素和环丙沙星。鲍曼不动杆菌对氨苄西林/舒巴坦的耐药率为41.4%,对美罗培南的耐药率为93.1%。根据分离株的抗菌药敏感性,患者接受美罗培南/ colistin(51.7%)或美罗培南/氨苄西林舒巴坦(48.3%)作为治疗方案。呼吸机相关性肺炎的临床反应,改善和衰竭分别在15(51.7%),8(27.6%)和6(20.7%)的患者中实现。结论:抗生素治疗对鲍曼不动杆菌(MDR A. baumannii)的VAP疗效相当,但死亡率高。考虑到与MDR感染相关的广泛且高死亡率,在医院中应用感染控制和抗生素管理计划至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号